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Abstract: Background: Women with urinary incontinence incur an increased risk of elevated 
postvoid residual (PVR) volume and impaired voiding efficiency (i.e., voided percentage (Void%)), 
but the clinical significance of these parameters remains poorly described. Further characterization 
of PVR and voiding efficiency may thus be useful in refining the evaluation and management of 
urinary incontinence. This study aims to explore possible circadian variations in PVR and Void% in 
older women with stress (SUI), urge (UUI) and mixed urinary incontinence (MUI). Methods: A 
single center prospective study which enrolled a convenience sample of 90 older women who 
consulted a tertiary referral hospital for urinary incontinence. Participants underwent an extensive 
medical interview and were hospitalized to complete a 24-h frequency-volume chart (FVC) with 
PVR measurement after each void (FVCPVR). Results: FVCPVR analysis demonstrated no differences 
in mean PVR and Void% between patients with SUI, UUI and MUI. Likewise, no daytime or 
nighttime differences were observed in mean PVR or Void% within or between groups. 
Conclusions: No evidence of circadian variation in PVR or Void% was observed in older women 
with SUI, UUI or MUI. 
Keywords: age; circadian; diagnostic; female; imaging; pathophysiology 
 
1. Introduction  
Postvoid residual (PVR) is the volume of urine that remains in the bladder after voluntary 
micturition [1]. An increased PVR (i.e., incomplete bladder emptying) may be a cause of lower 
urinary tract symptoms (LUTS) such as urgency, frequency, incontinence and nocturia and, in some 
cases, may also contribute to upper urinary tract dysfunction [2]. The voided percentage (Void%), 
defined by the International Continence Society (ICS) as the proportion of bladder content emptied 
[3], is even more strongly associated with peak flow rate (Qmax) [4], and may thus also be a clinically 
relevant variable in the evaluation of LUTS mediated by inefficient voiding.  
Although there is no consensus as to what volume constitutes an “elevated” PVR [5], and the 
specific cutoffs employed may vary across different LUTS, values of 50–100 mL are commonly 
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recognized as the floor threshold for abnormal [6], as PVR values in excess of 100 mL are exceedingly 
rare in middle-aged and older women [7]. Despite some heterogeneity across study populations, PVR 
values greater than 100 mL may be relatively more prevalent among women with stress urinary 
incontinence [8] and urge urinary incontinence [9]. 
Problematically, across all LUTS, significant intra-individual variability in PVR volumes and 
Void% generally exists, which hinders their potential diagnostic utility in LUTS management [2]. 
Recent research of uroflowmetry parameters in women with different subtypes of urinary 
incontinence indeed demonstrated high intra-individual variability in PVR volumes, but did not 
account for the potential influence of time-of-day on study results [10], which has been recognized as 
a potential confounding variable in the association between LUTS severity and PVR [11].  
Further characterization of the interplay between time-of-day, PVR and voiding efficiency may 
thus be useful in refining the evaluation and management of urinary incontinence. Although 
frequency-volume chart (FVC) data has, to our knowledge, never been recorded with PVR across a 
24-h period, previous small-scale research involving geriatric subjects with incontinence reported 
significantly higher intrasubject PVR values in the early morning compared to the afternoon or 
evening [11]. Accordingly, we aimed to test the hypothesis that PVR is greater in the nighttime vs. 
daytime in women with urinary incontinence. Secondly, we aimed to characterize circadian 
variations within and between subgroups of women with stress (SUI), urge (UUI) and mixed (MUI) 
urinary incontinence.  
2. Materials and Methods 
2.1. Study Design and Participants 
This study undertook a post hoc analysis of unpublished data from the Think Dry cross-sectional 
descriptive study of urinary incontinence in older adults. The study population consisted of a 
convenience sample who consulted a tertiary referral hospital for urinary incontinence from 
December 2013 to December 2018. Included were patients aged ≥ 65 years with a chief complaint of 
urinary incontinence. Exclusion criteria were a positive screen for cognitive impairment on the Mini-
Cog [12], symptomatic urinary tract infection and incontinence associated with recurrent infection, 
pain, hematuria, pelvic irradiation, radical pelvic surgery, suspected fistula or urinary retention. 
Local ethics committee approval (2013/950) was obtained, the Declaration of Helsinki was followed, 
and all participants provided written informed consent.  
2.2. Study Protocol 
All Think Dry participants completed a 24-h frequency-volume (FVC) chart and PVR (FVCPVR), 
a renal function profile (RFP) [13] and urodynamic testing. The data amassed were used by a 
functional urology specialist (K.E.) to establish specific diagnoses. Participants also completed several 
validated questionnaires, which were used to characterize their functional status (Belgian-modified 
Katz Index of Independence in Activities of Daily Living (ADL) [14]), frailty (Tilburg Frailty Indicator 
(TFI) [15]), fall risk (St. Thomas’s Risk Assessment Tool in Falling Elderly Inpatients (STRATIFY) [16]) 
and the impact of LUTS on their quality of life (International Consultation on Incontinence modular 
Questionnaire for LUTS in women (ICIQ-fLUTS) [17]).  
For the present analysis, female patients with a diagnosis of urodynamic stress incontinence 
and/or detrusor overactivity who completed a FVCPVR were included, such that 11 patients were 
excluded because urinary incontinence was not reproduced during urodynamic testing. 
2.3. Materials 
The Katz Index dichotomizes independence/dependence for six ADLs (bathing, dressing, 
transferring, toileting, continence and feeding). Scores are summated, such that a score of six reflects 
fully preserved function, four indicates moderate impairment, and ≤2 indicates severe functional 
impairment [18].  
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The TFI is a 15-item questionnaire assessing physical, psychological and social frailty, with 
increasing scores reflecting increased impairment in these domains. For this instrument, the 
maximum total score is 15, and patients with a score ≥ 5 may be deemed frail [15]. 
The STRATIFY instrument consists of five items that evaluate risk factors for falling. Scores 
range from zero to five, with a score ≥ 2 indicating high fall risk [16].  
The ICIQ-fLUTS questionnaire provides three subscores for filling (0–16), voiding (0–12) and 
incontinence symptoms (0–20), wherein higher scores correlate with symptom severity [17].  
All FVCPVR measurements were obtained by nurses of the inpatient urology department. Nurses 
recorded the voided volume (VV) (mL), urinary incontinence (UI) weight (g) and PVR (mL) 
accompanying each micturition, as well as patients’ time to bed with the intention of sleeping and 
time of awakening. PVR was analyzed noninvasively using a validated portable ultrasound device 
(BladderScan® BVI 9400, Verathon, Inc., Bothell, WA, USA) within 15 min after each micturition [19]. 
Patients were permitted to consume fluids and solids ad libitum in an effort to best simulate real-
world conditions. 
Measurements derived from the FVCPVR were defined in accordance with reports from the 
Standardization subcommittee of the ICS [1] [20]. Namely, global polyuria was defined as a 24-h 
urine output > 40 mL/kg; and nocturnal polyuria (NP) was defined as a nocturnal urine volume > 
33% of the total 24-h urine volume in the absence of global polyuria. Nocturia was defined as at least 
2 nocturnal voids, because this is the threshold at which most patients are more likely to report 
clinically significant nocturia-related bother and experience impaired health-related quality of life 
[21]. Voided percentage (Void%) was calculated as {(VV/[VV + PVR]) × 100} [3]. Missing values were 
not estimated or replaced, except in the case of one missing daytimevalue, for which values were 
replaced with corresponding mean daytime values for that patient (n = 9). 
Urodynamic studies were conducted according to local protocols, which were guided by current 
ICS recommendations [22].  
2.4. Statistical Analysis 
Between incontinence subgroups, continuous and categorical variables were compared using 
the Kruskal-Wallis and Fisher’s exact tests, respectively. A pairwise comparison using the Mann-
Whitney U and Fisher’s exact tests for continuous and categorical variables, respectively, was used 
to establish partial order between pairs when significant differences were identified on three-way 
analysis, with a Bonferroni correction (p < 0.017) applied for multiple comparisons. The Wilcoxon 
Signed-rank test was used to assess intragroup differences in PVR and Void%. Continuous variables 
are reported as median (confidence interval), and categorical variables are reported as frequency 
(percent). Data were analyzed using Statistical Package for Social Sciences (Version 24, IBM Corp., 
Armonk, NY, USA). 
3. Results 
3.1. Study Population 
A total of 90 patients were included, for which the median age was 76 (72–80) years and parity 
was 2 (1–3) children (Table 1). Most of the participants (98%) lived in the community, while two (2%) 
were nursing home residents. The distribution of hysterectomy (p = 0.031), depression (p = 0.048), 
neurological lesions (p = 0.023) and utilization of selective serotonin reuptake inhibitors (SSRIs) (p = 
0.032) were recorded differed between groups. History of hysterectomy was more prevalent in 
patients with SUI compared to UUI and MUI (57% vs. 28% and 27%, p = 0.019 and p = 0.026, 
respectively). Patients with UUI were more likely to be affected by depression compared to SUI (25% 
vs. 4%, p = 0.033). Neurological disorders were more prevalent in patients with UUI compared to SUI 
(31% vs. 4%, p = 0.008). SSRI utilization was greater among patients with UUI vs. SUI (28% vs. 4%, p 
= 0.017). No further significant pairwise differences were observed for these parameters. 
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Table 1. Patient characteristics. 
Variable 
All patients 
(n = 90) 
SUI 
(n = 28) 
UUI 
(n = 36) 
MUI 
(n = 26) 
p-Value 
Age (years) 76 (74–78) 74 (71–78) 77 (73–79) 78 (74–80) 0.345 
BMI (kg/m2) 28 (27–29) 28 (26–32) 28 (25–31) 28 (26–29) 0.872 
Gynecological history      
Parity 2 (2–3) 2 (1–3) 3 (2–3) 2 (1–3) 0.228 
vaginal deliveries 2 (2–2) 2 (1–2) 2 (2–3) 1 (1–2) 0.186 
cesarean deliveries 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0.382 
Hysterectomy 33 (37%) 16 (57%) 10 (28%) 7 (27%) 0.031 * 
Prolapse 68 (76%) 22 (79%) 25 (70%) 21 (81%) 0.583 
Comorbid conditions      
Chronic kidney disease 14 (15%) 1 (4%) 8 (22%) 5 (19%) 0.090 
Stage 3 12 (13%) 1 (4%) 7 (19%) 4 (15%)  
Stage 4 1 (1%) 0 1 (3%) 0  
Stage 5 1 (1%) 0 0 1 (4%)  
Diabetes mellitus 18 (20%) 8 (29%) 9 (25%) 1 (4%) 0.051 
Chronic obstructive 
pulmonary disease  
9 (10%) 4 (14%) 3 (8%) 2 (8%) 0.744 
Congestive heart failure  9 (10%) 3 (11%) 4 (11%) 2 (8%) 0.908 
Lower extremity venous 
insufficiency 
40 (44%) 11 (39%) 18 (50%) 11(42%) 0.687 
Sleep apnoea 5 (6%) 2 (7%) 3 (8%) 0 0.371 
Severe constipation 21 (23%) 7 (25%) 9 (25%) 5 (20%) 0.859 
Depression  15 (17%) 1 (4%) 9 (25%) 5 (20%) 0.048 * 
Neurological Disorders 18 (20%) 1 (4%) 11 (31%) 6 (23%) 0.023 * 
Stroke 7 (8%) 0 7 (20%) 0  
Parkinson’s disease 4 (4%) 0 2 (6%) 2 (8%)  
Normal pressure hydrocephalus 1 (1%) 0 0 1 (4%)  
Dementia 2 (2%) 0 1 (3%) 1 (4%)  
Inflammatory disease of CNS 1 (1%) 0 1 (3%) 0  
Peripheral neuropathy due to 
iatrogenic lesions 
1 (1%) 1 (4%) 0 0  
Postpolio syndrome 1 (1%) 0 0 1 (4%)  
Spinal canal stenosis 3 (3%) 0 2 (6%) 1 (4%)  
Medications      
Total medications 6 (5-7) 7 (5-8) 6 (4-7) 5 (3-7) 0.460 
α-adrenergic agonists 8 (9%) 4 (14%) 3 (8%) 1 (4%) 0.475 
α-adrenergic antagonists 0 0 0 0 - 
Angiotensin converting 
enzyme inhibitors 
9 (10%) 4 (14%) 2 (6%) 3 (12%) 0.553 
Anticholinergics 5 (6%) 1 (4%) 3 (8%) 1 (4%) 0.729 
Calcium channel blockers 17 (19%) 6 (21%) 4 (11%) 7 (27%) 0.268 
Cholinesterase inhibitors 3 (3%) 0 3 (8%) 0 0.111 
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Diuretics 18 (20%) 4 (14%) 9 (25%) 5 (19%) 0.601 
Loop diuretics 7 (8%) 1 (4%) 4 (11%) 2 (8%)  
Thiazide diuretics 2 (2%) 0 0 2 (8%)  
Potassium-sparing diuretics 3 (3%) 1 (4%) 1 (3%) 1 (4%)  
Carbonic anhydrase inhibitors 0 0 0 0  
Combination: loop and potassium 
sparing diuretics 
2 (2%) 1 (4%) 1 (3%) 0  
Combination: thiazide and 
potassium sparing diuretics 
4 (4%) 1 (4%) 3 (8%) 0  
Opioids 14 (16%) 5 (18%) 6 (17%) 3 (12%) 0.817 
Sedatives/hypnotics 16 (18%) 5 (18%) 7 (19%) 4 (15%) 0.941 
Antipsychotics 3 (3%) 1 (4%) 2 (6%) 0 0.777 
H1 blockers 10 (11%) 5 (18%) 3 (8%) 2 (8%) 0.481 
Selective serotonin reuptake 
inhibitors 
16 (18%) 1 (4%) 10 (28%) 5 (20%) 0.032 * 
Sodium-glucose cotransporter 
2 inhibitors 
0 0 0 0 - 
Note: Continuous variables are reported as median (95% confidence interval) and categorical 
variables are reported as frequency (percent). One value was missing for BMI. Chronic kidney disease 
(CKD), stage is consistent with KDIGO 2012 Clinical Practice Guideline for the evaluation and 
management of CKD [23]. Abbreviations: SUI—stress urinary incontinence; UUI—urge urinary 
incontinence; MUI—mixed urinary incontinence; BMI—body mass index; CNS—central nervous 
system. * Denotes statistical significance. 
For questionnaire data, the distribution of functional status (Katz Index) and frailty (TFI) 
significantly differed between subgroups. (Table 2). A greater proportion of patients with SUI 
reported a well-preserved ADL function compared to patients with UUI (93% vs. 47%, p < 0.001). 
Consistently, fewer patients with SUI reported severe ADL impairment compared to those with UUI 
(0% vs. 31%, p < 0.001). Frailty on the TFI was more prevalent among the UUI subgroup compared to 
patients with SUI (85% vs. 52%, p = 0.010). No further three-way or pairwise differences were 
observed in questionnaire analysis. 
Table 2. Functional status, frailty, risk factors for falling and LUTS-related quality of life. 
Variable 
All 
patients 
(n = 90) 
SUI  
(n = 28) 
UUI 
(n = 36) 
MUI 
(n = 26) 
p-Value 
Independence in ADLs 
(Katz Index) 
Total score (0–6) 
    < 0.001 * 
Severe Impairment (0–2) 13 (14%) 0 (0%) 11 (31%) 2 (8%)  
Moderate Impairment (3–4) 18 (20%) 2 (7%) 8 (22%) 8 (31%)  
Well-preserved function (5–6) 59 (66%) 26 (93%) 17 (47%) 16 (62%)  
Frailty (TFI) 
Total score (0–15) 
    0.017 * 
Nonfrail (0–4) 26 (30%) 13 (48%) 5 (15%) 8 (32%)  
Frail (5–15) 60 (70%) 14 (52%) 29 (85%) 17 (68%)  
Fall risk factors (STRATIFY) 
Total score (0–5) 
    0.201 
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Low/moderate risk (0–1) 51 (57%) 20 (71%) 18 (50%) 13 (52%)  
High risk (2–5) 38 (43%) 8 (29%) 18 (50%) 12 (48%)  
Lower urinary tract symptoms 
(ICIQ-fLUTS) 
     
Total score—Filling (0–16) 6 (6–7) 6 (5–6) 7 (6–7) 7 (5–9) 0.167 
Total score—Voiding (0–12) 1 (0–2) 1 (0–2) 2 (0–4) 1 (0–2) 0.346 
Total score—Incontinence (0–20) 11 (10–12) 11 (10–12) 11 (8–13) 11 (9–14) 0.823 
Note: Continuous variables are reported as median (95% confidence interval) and categorical 
variables as frequency (percent). Questionnaire data were missing for 4 patients for TFI; 1 patient for 
STRATIFY; and 1 patient for ICIQ-fLUTS. Abbreviations: SUI – stress urinary incontinence; UUI – 
urge urinary incontinence; MUI – mixed urinary incontinence; ADL- activities of daily living; TFI – 
Tilburg Frailty Indicator; STRATIFY – St. Thomas’s Risk Assessment Tool in Falling Elderly 
Inpatients; ICIQ-fLUTS – International Consultation on Incontinence modular Questionnaire for 
LUTS in women. (*) Denotes statistical significance. 
3.2. FVCPVR Characteristics 
The FVCPVR characteristics for each subgroup are presented in Table 3. Between subgroups, 
significant differences were observed in 24-h volume, proportion of patients with global polyuria, 
mean VV, 24-h maximum VV and total incontinence weight. The 24-h urine output was significantly 
higher in patients with SUI (2549 mL) vs. UUI (1747 mL) (p < 0.001) and in MUI (2173 mL) vs. UUI (p 
= 0.004). Consistently, global polyuria was more prevalent in patients with SUI (29%) vs. UUI (6%) (p 
= 0.016), and in patients with MUI (31%) vs. UUI (p = 0.013). The median number of voids in 24 h was 
higher in MUI (10 voids) vs. SUI (9 voids) (p = 0.010) or UUI (8 voids) (p = 0.003). Mean and maximum 
voided volumes were greater in patients with SUI (291 mL, 470 mL) than in UUI (177 mL, 335 mL) 
patients (p < 0.001, p < 0.001) and MUI (181 mL, 320 mL) patients (p = 0.002, p = 0.001). No pairwise 
differences were observed in incontinence weight after Bonferroni correction. 
Table 3. FVCPVR characteristics. 
 
All patients 
(n = 90) 
SUI 
(n = 28) 
UUI 
(n = 36) 
MUI 
(n = 26) 
p-Value 
24-h volume (mL) 
2086 (1827–
2260) 
2549 (2120–
2852) 
1747 (1430–
2000) 
2173 (1827–
2523) 
< 0.001 * 
Global polyuria (24-h urine 
output > 40 mL/kg) 
18 (20%) 8 (29%) 2 (6%) 8 (31%) 0.013 * 
Nocturia (≥ 2 voids/night) 60 (67%) 19 (68%) 22 (61%) 19 (73%) 0.586 
Nocturnal polyuria 
(NPi > 33%) 
63 (70%) 17 (85%) 25 (74%) 12 (67%) 0.294 
Number of voids (24 h) 9 (8–9) 9 (8–10) 8 (7–9) 10 (9–12) 0.005 * 
Mean VV (mL) 200 (180–241) 
291 (233–
325) 
177 (157–
200) 
181 (151–
245) 
< 0.001 * 
Max VV (mL) 380 (340–400) 
470 (400–
500) 
335 (225–
400) 
320 (250–
400) 
< 0.001 * 
Total UI weight (g) 45 (19–90) 15 (0–46) 88 (14–265) 48 (22–236) 0.040 * 
Mean 24-h PVR (mL) 26 (20–36) 28 (16–39) 27 (10–43) 24 (11–45) 0.837 
Mean daytime PVR (mL) 20 (11–30) 22 (10–44) 17 (7–32) 22 (4–37) 0.658 
Mean nighttime PVR (mL) 20 (12–42) 20 (9–68) 16 (3–44) 31 (10–55) 0.511 
Max 24-h PVR (mL) 92 (67–135) 105 53–156) 77 (40–126) 
115 (63–
191) 
0.463 
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Mean 24-h Void% (%) 90 (87–90) 91 (87–94) 89 (80–95) 91 (85–95) 0.729 
Mean daytime Void% (%) 91 (88–94) 91 (85–96) 91 (82–96) 92 (84–98) 0.876 
Mean nighttime Void% (%) 91 (87–96) 94 (84–98) 92 (83–98) 91 (84–98) 0.884 
Min 24-h Void% (%) 64 (56–72) 68 (58–75) 59 (49–81) 64 (41–83) 0.555 
Note: Continuous variables are reported as median (95% confidence interval) and categorical 
variables as frequency (percent). Abbreviations: FVCPVR—frequency-volume chart with postvoid 
residual volume; SUI—stress urinary incontinence; UUI—urge urinary incontinence; MUI—mixed 
urinary incontinence; NPi—nocturnal polyuria index = proportion of nocturnal urine volume of the 
total 24-h urine volume in the absence of global polyuria; VV—voided volume; UI—urinary 
incontinence; PVR—postvoid residual; Void%—voided percentage = (VV/[VV + PVR]) × 100%). (*) 
Denotes statistical significance. 
No circadian differences were observed in mean PVR or Void% between subgroups. Moreover, 
within groups, no significant differences were observed between daytime and nighttime mean PVR 
for SUI (22 vs. 20 mL, p = 0.764), UUI (17 vs. 16 mL, p = 0.905), or MUI (22 vs. 31 mL, p = 0.107). 
Likewise, no significant intragroup difference was observed between daytime and nighttime Void% 
for SUI (91 vs. 94%, p = 0.394), UUI (89 vs. 91%, p = 0.617), or MUI (92 vs. 91%, p = 0.977). The 
distribution of mean 24-h and maximum daytime PVR is presented in Table 4. 
Table 4. Distribution of mean 24-h and maximum daytime PVR. 
 
All patients 
(n = 90) 
SUI 
(n = 28) 
UUI 
(n = 36) 
MUI 
(n = 26) 
p-Value 
Mean 24-h PVR      0.781 
< 50 mL 66 (73%) 20 (71%) 27 (75%) 19 (73%)  
50–100 mL 18 (20%) 7 (25%) 7 (19%) 4 (15%)  
> 100 mL 6 (7%) 1 (4%) 2 (6%) 3 (12%)  
Max daytime PVR     0.499 
< 50 mL 39 (43%) 11 (39%) 16 (44%) 12 (46%)  
50–100 mL 21 (23%) 8 (29%) 10 (28%) 3 (12%)  
> 100 mL 30 (33%) 9 (32%) 10 (28%) 11 (42%)  
Note: Variables are reported as frequency (percent). Abbreviations: SUI—stress urinary incontinence; 
UUI—urge urinary incontinence; MUI—mixed urinary incontinence; PVR—postvoid residual. 
* Denotes statistical significance. 
4. Discussion 
To our knowledge, this is the first study to utilize the 24-h FVC with PVR volume to characterize 
the circadian pattern of PVR and Void% in older women with SUI, UUI and MUI. In the present 
analysis, no significant circadian variations were observed in mean PVR or Void% within subgroups.  
Abnormal residual volume is a common phenomenon in the setting of urinary incontinence. 
Although there is no consensus as to what exactly constitutes an elevated PVR, many experts have 
proposed values between 50–100 mL as the lower threshold for abnormal residual urine volume [24]. 
In their analysis of PVR in middle-aged women with urodynamic stress incontinence, Tseng et al. 
recognized that more than one-third of participants had a PVR > 50 mL, and nearly one in five 
experienced a PVR > 100 mL [8]. Consistently, in the present analysis, a maximum daytime PVR >50 
mL was identified in more than half of all participants, and a maximum daytime PVR > 100 mL was 
recorded in one-third of all subjects.  
Importantly, however, while more than one-fourth of all participants in the present study 
demonstrated mean 24-h PVR > 50 mL, only 7% of all patients experienced a PVR > 100 mL. Thus, 
single point-of-care PVR measurements may overestimate the true prevalence of an abnormal 
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residual urine volume, particularly when higher cutoffs (e.g., PVR ≥ 100 mL) are applied. Differences 
in maximum daytime PVR and mean 24-h PVR are most likely a function of the number of 
measurements, as significant interindividual in PVR has been previously reported [20]. Indeed, this 
is consistent with data from Saaby and colleagues on the repeatability of PVR ≥ 100 mL among 
women with uro-gynecological complaints, wherein the prevalence of PVR ≥ 100 was 14%, but 
declined to 1.3% on repeated measurements [25]. 
The present post hoc study design is limited by the absence of a prospective power analysis, lack 
of a concomitant control group and small sample size. Moreover, the convenience sample of patients 
recruited from a tertiary referral hospital might introduce selection biases in this study and limits the 
generalizability of this study beyond older women with urinary incontinence. Data about urinary 
tract infection and stage of prolapse are missing and may be confounding factors that may influence 
the PVR. Measurement errors cannot be excluded, given that a team of nurses was responsible for 
the PVR measurements, and interrater reliability was not examined.  
In addition, this study relied on 24-h FVCs, which are considered to be less reliable than FVCs 
of longer duration [26]. Given that there are currently no patient-centered equipment options for 
home measurement of PVR, the present study design necessitated hospitalization, which is not a 
viable option in the real-world evaluation of urinary incontinence amongst community-dwelling 
adults. Future studies should aim to validate our results using three-day FVCPVR instruments and 
establish precise cut-off values for clinically significant PVR elevations.  
Overall, the present study suggests that bladder emptying is comparable in efficacy during the 
nighttime versus daytime. Moreover, there is no evidence to suggest that measurements of PVR may 
differentiate the clinical diagnoses of SUI, UUI and MUI in older women. Multiple PVR 
measurements may be needed to increase intrasubject reliability 
5. Conclusions 
The present analysis did not identify significant circadian variation in mean PVR or Void% 
among older women with stress, urge or mixed urinary incontinence. This study is the first to utilize 
the 24-h FVC with PVR volume to characterize the circadian pattern of PVR and Void% in older 
women with SUI, UUI and MUI, which may have bearing on the rational use and interpretation of 
one-time point-of-care PVR testing 
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